Kornimate/medical-research-clean huggingface dataset:
postoperative exercise training and colorectal cancer liver metastasis

Conditions: Cancer Metastatic to Liver; Cancer Colorectal

Summary: up to 25% of colorectal cancer (crc) patients are diagnosed with liver metastases, which is the most common site of metastasis, already during the primary tumor diagnosis. another 30% of the patients will develop liver metastases at a later stage. even though patient can be treated by surgical resection of the metastatic tumor, 50-75% of the patients experience a relapse in less than two years. due to the high probability of relapse, mcrc patients undergo multiple rounds of surgery and adjuvant treatment (chemotherapy/radiotherapy) which results in substantial physical de-conditioning. physical activity has been shown to increase the progression-free survival rates in mcrc patients, when applied post-diagnosis. increased cardiorespiratory fitness (vo2peak) at the time of diagnosis among crc individuals has been associated with lower risk of all-cause mortality. although data on the effect of chronic exercise on vo2peak have emerged, thus far, there is no randomized clinical trial that has investigated the effects of exercise training in mcrc patients early after surgical treatment with curative intent. therefore, this project aims to address the beneficial effect of structured exercise training primarily on vo2peak and tumor recurrence in mcrc patients immediately after surgical treatment and while they are undergoing adjuvant chemotherapy/radiotherapy. a total of 66 participants will be recruited from the department of surgery and transplantation, rigshospitalet and randomly allocated to a standard care control group (n=22), standard care plus 150 min/week exercise training (n=22) or standard care plus 300 min/week exercise training (n=22). participants will undergo exercise training for 6 months, starting immediately after surgery, and they will be followed for additional 6 months. tumor recurrence will be evaluated up to 3 years after training initiation.


Eligibility criteria:
inclusion criteria: * colorectal cancer patients diagnosed with liver metastasis and scheduled for liver metastasis surgical resection exclusion criteria: * age \<18 * pregnancy * physical or mental disabilities that prohibit execution of test or training procedures * inability to understand the danish language.
icotinib versus placebo as adjuvant therapy in egfr-mutant lung adenocarcinoma

Conditions: EGFR Positive Non-small Cell Lung Cancer; Adenocarcinoma

Summary: the purpose of this study is to compare 3years of disease-free survival (dfs) of icotinib and placebo in the treatment of patients who egfr mutation-positive ii-iiia lung adenocarcinoma.

this study is designed to compare 3 years of disease-free survival (dfs) of icotinib and placebo in the treatment of patients who egfr mutation-positive ii-iiia lung adenocarcinoma. primary outcome measure: disease-free survival between icotinib group and placebo group. secondary outcome measures: overall survival between icotinib group and placebo group. lung cancer symptoms and health-related quality of life (hrqol) . number of participants with adverse events.

Eligibility criteria:
inclusion criteria: * pathologically confirmed lung adenocarcinoma after surgical resection * stage ii-iiia disease according to 7th edition of tnm staging * patients must harbor sensitive egfr gene mutation (19/21) * received four cycles of platinum-based adjuvant chemotherapy.there are many different kinds of chemotherapy regimens including vinorelbine, gemcitabine, docetaxel, paclitaxel, pemetrexed plus cisplatin or carboplatin.the first cycle of chemotherapy with cisplatin dose of 75 mg / m2 ± 10% or carboplatin auc = 5 ± 10% to calculate the dose of chemotherapy exclusion criteria: * previous systemic anti-tumor therapy, including chemotherapy or targeted therapy(including but not limited to monoclonal antibodies, small molecule tyrosine kinase inhibitor, etc * presence of metastatic disease * other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ * any unresolved chronic toxicity from previous anticancer therapy * received antitumor radiation therapy (except for the stage iiia n2 patients who received adjuvant radiotherapy after surgery)
dose finding trial of rosuvastatin and atorvastatin versus hepatitis c

Conditions: Hepatitis C

Summary: different doses of rosuvastatin and atorvastatin will be used to see if hcv viral load changes and liver tests change.


Eligibility criteria:
inclusion criteria: * hepatitis c exclusion criteria: * hiv positivity
the use of dermabond versus standard staple for wound closure in children with neuromuscular scoliosis undergoing spinal deformity correction surgery

Conditions: Wounds

Summary: this is a prospective, phase ii (hypothesis generating) randomized pilot study investigating the efficacy of using dermabond as a method of final wound closure as compared to the standard staple method in children with neuromuscular scoliosis undergoing spinal deformity correction surgery.

1. to explore whether there is a difference in the incidence of wound infection in the dermabond group vs. the skin staple group as measured by microbiological culture four days post-operatively. wound infection is defined as prolonged sterile discharge (\>4 days), positive wound cultures, or cellulitis four or more days post-operatively. 2. to explore whether there is a difference in the cosmetic result of the wound closure as measured by the hollander wound evaluation scale. our hypothesis is that the dermabond group will have a better cosmetic result. secondary outcome 3. to explore whether there is a difference in the time for final wound closure. our hypothesis is that the dermabond group will have a shorter time for final wound closure. secondary outcome 4. to explore whether there is a difference in mean caregiver/parental satisfaction scores as measured by a visual analog scale. our hypothesis is that parental satisfaction will be higher in the dermabond group. secondary outcome

Eligibility criteria:
inclusion criteria: * male or female 19 years or younger * neuromuscular scoliosis * undergoing posterior spinal instrumentation and fusion (one stage) exclusion criteria: * other non-neuromuscular causes of scoliosis * previous history of spinal surgery * previous incision over the operative site * history of keloid formation * allergy to superglue * use of anticoagulation therapy

Keywords: neuromuscular scoliosis dermabond infection wound closure
gemcitabine, oxaliplatin and capecitabine for advanced pancreatic carcinoma

Conditions: Locally Advanced Pancreatic Cancer; Metastatic Pancreatic Cancer

Summary: gemcitabine is the mainstay of palliative chemotherapy for patients with advanced pancreatic cancer (apc). recent randomized trials have shown increased clinical benefit with the addition of oxaliplatin and prolonged median survival with the addition of capecitabine to gemcitabine. gemcitabine, capecitabine and oxaliplatin are 3 newer, well tolerated anticancer drugs with mild and non-overlapping toxicity profiles. we therefore propose a dose-finding and safety study of the triple combination gemcitabine, capecitabine and oxaliplatin in patients with apc (phase i part), followed by a phase ii part to assess preliminary efficacy of this triple combination.

primary objectives: * phase i: to determine the maximum tolerated dose (mtd) of oxaliplatin in combination with gemcitabine and capecitabine (gemoxel) in patients with apc * phase ii: to assess any anti-tumor activity of gemoxel in patients with apc secondary objectives: * to assess toxicity and safety of the combination treatment gemoxel in patients with apc primary endpoints: * phase i: dose-limiting toxicity * phase ii: objective tumor response secondary endpoints: * toxicity at mtd according to nci ctc 3.0 * progression-free survival and overall survival

Eligibility criteria:
inclusion criteria: * cytologically or histologically confirmed adenocarcinoma of the exocrine pancreas * disease non-resectable and locally advanced or metastatic * measurable disease or evaluable disease i.e. tumor marker ca19-9 at baseline ≥ 1.5 x upper limit of normal (uln) * age \>18 years * karnofsky performance status ≥ 60% * life expectancy of at least 3 months * written informed consent * willing and able to comply with the protocol for the duration of the study exclusion criteria: * prior chemotherapy for pancreatic cancer * prior adjuvant radio- or radiochemotherapy for pancreatic cancer within 12 months of inclusion * known cns metastases at the time of enrollment * neutrophil count ≤ 1.5 x109/l, platelet count ≤100 x109/l, hemoglobin ≤ 10g/dl * serum creatinine \> 1.25 x uln * asat, alat and alkaline phosphatase \> 2.5 uln or \> 5 uln in the presence of liver metastasis, bilirubin \> 1.5 uln (after treatment of obstructive jaundice eg. stent) * pregnant or breast feeding women (women of childbearing potential must have a negative pregnancy test at baseline) * men and women of reproductive potential who are not using an effective method of contraception * clinically significant cardiac disease (nyha iii-iv) or myocardial infarction within the last 12 months * neurological disease with dys-/paraesthesias \> grade 1 according to nci ctc * any serious concomitant disorder incompatible with the trial (in the judgement of the investigator) * psychiatric disability thought to be clinically significant in the opinion of the investigator precluding informed consent or interfering with compliance

Keywords: advanced pancreatic cancer palliative chemotherapy first-line therapy capecitabine oxaliplatin gemcitabine dose-finding study phase ii
charge: a text messaging-based weight loss intervention

Conditions: Weight Loss; Obesity

Summary: this study evaluates different versions of a text messaging-based app for weight loss. this study will place participants to 1 of 32 experimental conditions that reflect different texting components and levels. participants will be randomized to a condition. the investigators will recruit 448 adults into a 6-month weight loss program, with an additional follow-up 6-months after the intervention ends.

standalone text messaging-based weight loss treatments are scalable and can achieve population reach. however, these interventions are also modular; they can be delivered independently to maximize cost-effectiveness or combined with other approaches (e.g. provider counseling) to maximize outcomes. this study is a 12-month experimental trial among 448 adults with obesity. all participants will receive a core 6-month weight loss texting intervention that includes tailored behavior change goals, interactive self-monitoring, automated feedback, and skills training. participants will be randomly assigned to 1 of 32 different experimental conditions.

Eligibility criteria:
inclusion criteria: * males and females aged 18-65 years * participants have english language proficiency * participants have a bmi between 25-40 kg/m2 * participants will own a smartphone * participants will be willing to receive multiple text messages daily. exclusion criteria: * prior or planned bariatric surgery * psychiatric hospitalization in past 12 months * pregnancy, nursing, or planned pregnancy * history of a cardiovascular event * history of an eating disorder * history of a condition (e.g., end stage renal disease, cancer, schizophrenia) or use of medications (e.g., lithium, steroids, anti-psychotics) that would affect weight measurement, for which weight loss is contraindicated, or might promote weight change * current participation in a weight loss trial and/or recent weight loss \> 10% * investigator discretion for safety reasons

Keywords: text message digital health weight loss personalized
implementation of a self-help depression program among orthopedic patients

Conditions: MDD

Summary: the proposed study addresses the potential utility of providing an accessible self-help intervention for patients in a medical setting with an estimated diagnosis of mdd. specifically, the study will explore whether a) such an intervention can be effectively implemented in a primary care setting and b) patients originally seeking medical attention for an orthopedic problem will be willing to seek psychological treatment and, c) improvement in depression symptoms will lead to improvement in upper and lower extremity functioning.

the present project will be an open-label trial to assess the feasibility and acceptability of a self-help intervention among a sample of orthopedic patients. in addition to monitoring the effectiveness of the deprexis program on depressive symptoms, the proposed project will assess whether a reduction in depressive symptoms will be associated with improvement on patient reported orthopedic impairment. the investigators will enroll 50 adults and the participants will be given the opportunity to participate in 8 weeks of the web-based online deprexis program.

Eligibility criteria:
inclusion criteria: * all patients older than 18 years who present to a surgeon with an upper or lower extremity injury or disability at a participating center (see attached list) * a level of clinical depression more than minimal symptoms as defined by a score ≥ 10 on the patient health questionnaire-9 (phq-9) * willing and able to provide informed consent and comply with the protocol exclusion criteria: * injury or illness best treated with prompt surgery
optimization of remotely delivered physical activity intervention for breast cancer survivors

Conditions: Breast Cancer Female; Physical Activity

Summary: the overall objective of the proposed research is to pilot test the feasibility and acceptability of a set of more scalable technology-supported physical activity promotion intervention strategies in breast cancer survivors using tmultiphase optimization strategy trial (most) methodology. most involves highly efficient randomized experimentation to assess the effects of individual intervention strategies, and thereby identify which strategies and what strategy levels make the important contributions to the overall program's effect on physical activity. this information then guides assembly of an optimized physical activity program, that achieves target outcomes with least resource consumption and participant burden. the resulting intervention will have great potential for scalability because it uses technology (smartphones) participants already own and requires no on-site visits.


Eligibility criteria:
inclusion criteria: 1. diagnosed with stage i-iii breast cancer within the last 5 years 2. have completed last cancer treatment (adjuvant chemotherapy, radiation therapy or surgery) at least 3 months prior to enrollment 3. english speaking 4. currently participate in less than 60 minutes of moderate and vigorous physical activity per week 5. own a smartphone 6. have access to a computer with internet 7. participants may be using adjuvant endocrine therapies. 8. willing to be waitlisted for future wave if current wave reaches capacity exclusion criteria: -women will be excluded if they report any of the following: 1. respiratory, joint or cardiovascular problems precluding physical activity 2. metastatic disease 3. planned elective surgery during duration of the intervention/follow-up that would interfere with participation (e.g., breast reconstructive surgery). only if participating in optional blood collection: 1. a prior cardiovascular event (i.e. stroke, myocardial infarction) 2. have been diagnosed with an acute or chronic immune system medical conditions, or conditions that impact immune and endocrine function (e.g., cfs, lupus, rheumatoid arthritis, hepatitis c, or immunosuppressive treatment requiring conditions)
comparison of pantoprazole and ranitidine in dyspepsia

Conditions: Dyspepsia

Summary: the h0 hypothesis of the study is there is no difference between pantoprazole and ranitidine in treating patients presented with dyspepsia to the emergency department. the h1 hypothesis is there is difference between pantoprazole and ranitidine in treating patients presented with dyspepsia to the emergency department.

dyspepsia is one of the common complaints in emergency department. proton pomp inhibitors, h2 receptor blockers and anti-acids are common drugs for treating dyspepsia in emergency department. however there is no study in the emergency department comparing the effectiveness of these drugs. so the investigators planned this study which drug is effective in these patients in order to provide a cost-effective treatment in dyspeptic patients.

Eligibility criteria:
inclusion criteria: * epigastric pain * older than 18 years old exclusion criteria: * diagnosed as cholecystitis, pancreatitis, myocardial infarction, etc.. at the end of the emergency deparment evaluation period. * pregnancy * patients with unstable vital signs * patients used anti-acid, h2 receptor blockers and proton pomp inhibitors in the last one hour. * allergy to h2 receptor blockers and proton pomp inhibitors. * patients denied to give inform consent and who are illiterate

Keywords: dyspepsia pantoprazole ranitidine emergency department
pelvic floor exercises versus pilates on urinary incontinance in chronic obstructive pulmonary disease

Conditions: Urinary Incontinence

Summary: the aim of the study is to compare between the effect of both pelvic floor and pilates exercises on urinary incontinences in copd patients.

urinary incontinence (ui) is defined as loss of bladder control and is characterized by the complaint of any involuntary leakage of urine ui is an important individual and social problem, in that it is associated with worse health-related quality of life (hrqol) in subjects with chronic obstructive pulmonary disease. although ui is not a life-threatening condition, it is common and can have numerous negative psychological, social, and economical effects. women with ui in the general population have higher levels of depression, anxiety and stress, poor sleep quality and significantly lower hrql additionally, long term ui may result in absence from work, increased healthcare costs, social isolation and physical inactivity which is common from the early stages of the copd due to dyspnea. furthermore, inactivity is associated with risk of hospital admissions and is a strong predictor for mortality. the combination of ui and copd may therefore result in a double risk factor in terms of exercise avoidance and the subsequent negative consequences of inactivity. as it could be concluded that urinary incontinence is a trouble problem that can change the life of copd patients and therapy attempts to prevent it or control it will be appreciated, taking in consideration that all people nowadays prefer to choose the most safe method of their conditions.

Eligibility criteria:
inclusion criteria: * patients diagnosed with copd \& urinary incontinence * stable with moderate to severe copd * their ages will range from fifty years old. * all patients will be clinically stable. exclusion criteria: * gynecologic surgery ( 6 months prior to study) * current urinary tract infection * uncontrolled diabetes mellitus * diagnosed with psychiatric or depressive disorder * existing arterial aneurysm. * clinical signs of unstable cardiac event (eg, congestive heart failure), * severe arterial hypertension, * neurological disorders that will affect pelvic floor muscles. * acute copd exacerbation within the last 4 weeks. * any need for supplemental oxygen.
the effects of mls laser therapy in patients with chronic nonspecific neck pain

Conditions: Chronic Non-specific Neck Pain

Summary: non-specific cronic low back pain is very common condition affecting 30-50% of adults. it is featured by neck muscles contractures which lead to pain and reduction of cervical spine mobility. high intensity laser therapy has been shown to be an effective treatment to improve symothoms in patient with non-specific neck pain. the aim of this study is to assess the effects of a multi-wave locked system laser therapy in patient with non-specif neck pain.


Eligibility criteria:
inclusion criteria: * chronic low back pain (\> 3 months) * body mass index \< 30 * preserved cognitive ability to fully understand and observe indications received by medical personnel * ability to understand and give an informed consent exclusion criteria: * spine surgery * spinal hernia * spondylolisthesis * spinal infections * severe spine deformities * neural diseases * upper limbs radiculopathy * cervical rib * rotator cuff or other shoulder diseases * rheumatic diseases * diabetes * psychiatric diseases * vascular diseases * cancer * infectious diseases * skin abrasion * pregnancy or breastfeeding * recent injuries * known sensibility to laser therapy * epilepsy * anticoagulant therapy * pacemaker * hemorrhagic diathesis * photosensitizing drugs * known photosensibility * neck tattoos
a study to investigate the safety, tolerability and blood levels of gsk598809

Conditions: Substance Dependence

Summary: gsk598809 is being developed to facilitate overcoming an addiction to nicotine and to help people stop smoking. this study will investigate if gsk598809 is safe and tolerated in people who smoke and will also look at blood levels of gsk598809 and nicotine.


Eligibility criteria:
inclusion criteria: * healthy adult male smoker between the ages of 18 and 50 years * body weight greater than 50kg and bmi between 18.5-29.9 kg/m2. * no abnormalities on the medical, psychiatric or laboratory evaluation * smoke on average more than 20 but less that 40 cigarettes per day for the past year and not tried to give up in the 3 months before the study. exclusion criteria: * history of psychiatric disorder or sleep disorder. * receiving treatment for smoking cessation. * use tobacco products other than cigarettes.

Keywords: healthy volunteers, tolerability, pharmacokinetics, pharmacodynamics safety, smoking,